SUN-078 - Pituitary apoplexy in pregnancy with threatened vision

Background: Pituitary apoplexy is an acute, life-threatening syndrome caused by hemorrhage or infarction of the pituitary gland, usually within a pre-existing adenoma. During pregnancy, the risk of apoplexy increases due to physiologic pituitary enlargement, lactotroph hyperplasia, and pregnancy-related hemodynamic and coagulation changes. This is the first case report of third-trimester pituitary apoplexy managed with simultaneous surgical decompression and delivery in the same OR.

Case description: A previously healthy 30 year-old female (G2T1P0A1L1) presented at 37w4d with bilateral blurry vision and was found to have bitemporal hemianopia. CT head revealed a sellar mass with optic chiasm compression. She was admitted to neurosurgery and underwent urgent Caesarean section followed by endoscopic transsphenoidal resection/decompression within the same OR. Post-operatively, she developed central adrenal insufficiency and central hypothyroidism requiring hormone replacement. She was unable to breastfeed due to inappropriately low-normal postpartum prolactin and did not respond to a domperidone trial. Although she experienced polyuria postpartum, there was no evidence of central diabetes insipidus, and polyuria was attributed to normal postpartum diuresis.

Discussion: To our knowledge, this is the first reported case of concurrent Caesarean section and transsphenoidal decompression for third-trimester pituitary apoplexy. Neuroophthalmological symptoms require urgent neurosurgical intervention regardless of gestational age. Clinicians should anticipate possible post-operative hypopituitarism and lactation failure. Given the increased recurrence risk of apoplexy in future pregnancies, preconception counseling with neurosurgery, endocrinology, and obstetrics is recommended.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*